Hannah P Yang1, Alan Meeker2, Richard Guido3, Marc J Gunter4, Gloria S Huang5, Patricia Luhn6, Lori d'Ambrosio3, Nicolas Wentzensen6, Mark E Sherman6,7. 1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, 9609 Medical Center Drive, Room #7E238, Bethesda, MD, 20892-9774, USA. yanghan@mail.nih.gov. 2. Johns Hopkins University, Baltimore, MD, USA. 3. Magee Women's Hospital of the UPMC System, Pittsburgh, PA, USA. 4. Imperial College London, London, UK. 5. Obstetrics and Gynecology and Women's Health; and Molecular Pharmacology, Albert Einstein Cancer Center, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA. 6. Division of Cancer Epidemiology and Genetics, National Cancer Institute, 9609 Medical Center Drive, Room #7E238, Bethesda, MD, 20892-9774, USA. 7. Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA.
Abstract
PURPOSE: Clonal loss of PTEN expression occurs frequently in endometrial carcinoma and endometrial hyperplasia. Limited data from immunohistochemical studies suggest that PTEN-null appearing endometrial glands are detectable in women without pathologic abnormalities, but the relationship of PTEN expression to endometrial cancer risk factors has not been extensively explored. We evaluated relationships between endometrial cancer risk factors and loss of PTEN expression in a set of benign endometrial samples prospectively collected from women undergoing hysterectomy and in endometrial cancer tissues from a population-based case-control study. METHODS: We used a validated PTEN immunohistochemical assay to assess expression in epidemiological studies designed to assess benign endometrium [Benign Reproductive Tissue Evaluation Study (n = 73); Einstein Endometrium Study (n = 19)], and endometrial cancer [Polish Endometrial Cancer Study (n = 148)] tissues. Associations between endometrial cancer risk factors (collected via study-specific risk factor questionnaires) and PTEN expression in endometrial tissues were determined using Fisher's exact tests. RESULTS: PTEN loss was detected in 19% of benign endometrial tissues versus 55% in endometrial cancers. NSAID use was statistically significantly associated with PTEN loss in the benign endometrium (p = 0.02). CONCLUSION: Our data demonstrate that PTEN loss is detectable in endometrial tissues that are benign and malignant, with substantially more frequent loss in endometrial cancer compared with benign endometrium. However, alterations in expression were unrelated to most risk factors in this analysis, except for the association with NSAID use, which may represent a chance finding or reverse causality among patients with endometriosis who may have PTEN pathway abnormalities in eutopic endometrium. Further evaluation of factors associated with PTEN loss and long-term follow-up of women with PTEN-null endometrial glands may be useful in understanding early events in endometrial carcinogenesis.
PURPOSE: Clonal loss of PTEN expression occurs frequently in endometrial carcinoma and endometrial hyperplasia. Limited data from immunohistochemical studies suggest that PTEN-null appearing endometrial glands are detectable in women without pathologic abnormalities, but the relationship of PTEN expression to endometrial cancer risk factors has not been extensively explored. We evaluated relationships between endometrial cancer risk factors and loss of PTEN expression in a set of benign endometrial samples prospectively collected from women undergoing hysterectomy and in endometrial cancer tissues from a population-based case-control study. METHODS: We used a validated PTEN immunohistochemical assay to assess expression in epidemiological studies designed to assess benign endometrium [Benign Reproductive Tissue Evaluation Study (n = 73); Einstein Endometrium Study (n = 19)], and endometrial cancer [Polish Endometrial Cancer Study (n = 148)] tissues. Associations between endometrial cancer risk factors (collected via study-specific risk factor questionnaires) and PTEN expression in endometrial tissues were determined using Fisher's exact tests. RESULTS:PTEN loss was detected in 19% of benign endometrial tissues versus 55% in endometrial cancers. NSAID use was statistically significantly associated with PTEN loss in the benign endometrium (p = 0.02). CONCLUSION: Our data demonstrate that PTEN loss is detectable in endometrial tissues that are benign and malignant, with substantially more frequent loss in endometrial cancer compared with benign endometrium. However, alterations in expression were unrelated to most risk factors in this analysis, except for the association with NSAID use, which may represent a chance finding or reverse causality among patients with endometriosis who may have PTEN pathway abnormalities in eutopic endometrium. Further evaluation of factors associated with PTEN loss and long-term follow-up of women with PTEN-null endometrial glands may be useful in understanding early events in endometrial carcinogenesis.
Authors: Veronica Wendy Setiawan; Rayna K Matsuno; Galina Lurie; Lynne R Wilkens; Michael E Carney; Brian E Henderson; Laurence N Kolonel; Marc T Goodman Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-06-04 Impact factor: 4.254
Authors: Annette S Neill; Christina M Nagle; Melinda M Protani; Andreas Obermair; Amanda B Spurdle; Penelope M Webb Journal: Int J Cancer Date: 2012-07-27 Impact factor: 7.396
Authors: G L Mutter; M C Lin; J T Fitzgerald; J B Kum; J P Baak; J A Lees; L P Weng; C Eng Journal: J Natl Cancer Inst Date: 2000-06-07 Impact factor: 13.506
Authors: Nicolas Wentzensen; Jamie N Bakkum-Gamez; J Keith Killian; Joshua Sampson; Richard Guido; Andrew Glass; Lisa Adams; Patricia Luhn; Louise A Brinton; Brenda Rush; Lori d'Ambrosio; Munira Gunja; Hannah P Yang; Montserrat Garcia-Closas; James V Lacey; Jolanta Lissowska; Karl Podratz; Paul Meltzer; Viji Shridhar; Mark E Sherman Journal: Int J Cancer Date: 2014-03-31 Impact factor: 7.396
Authors: Celeste Leigh Pearce; Claire Templeman; Mary Anne Rossing; Alice Lee; Aimee M Near; Penelope M Webb; Christina M Nagle; Jennifer A Doherty; Kara L Cushing-Haugen; Kristine G Wicklund; Jenny Chang-Claude; Rebecca Hein; Galina Lurie; Lynne R Wilkens; Michael E Carney; Marc T Goodman; Kirsten Moysich; Susanne K Kjaer; Estrid Hogdall; Allan Jensen; Ellen L Goode; Brooke L Fridley; Melissa C Larson; Joellen M Schildkraut; Rachel T Palmieri; Daniel W Cramer; Kathryn L Terry; Allison F Vitonis; Linda J Titus; Argyrios Ziogas; Wendy Brewster; Hoda Anton-Culver; Alexandra Gentry-Maharaj; Susan J Ramus; A Rebecca Anderson; Doerthe Brueggmann; Peter A Fasching; Simon A Gayther; David G Huntsman; Usha Menon; Roberta B Ness; Malcolm C Pike; Harvey Risch; Anna H Wu; Andrew Berchuck Journal: Lancet Oncol Date: 2012-02-22 Impact factor: 41.316
Authors: Theodore M Brasky; Ashley S Felix; David E Cohn; D Scott McMeekin; David G Mutch; William T Creasman; Premal H Thaker; Joan L Walker; Richard G Moore; Shashikant B Lele; Saketh R Guntupalli; Levi S Downs; Christa I Nagel; John F Boggess; Michael L Pearl; Olga B Ioffe; Kay J Park; Shamshad Ali; Louise A Brinton Journal: J Natl Cancer Inst Date: 2017-03-01 Impact factor: 13.506
Authors: Melissa A Merritt; Howard D Strickler; Mark H Einstein; Hannah P Yang; Mark E Sherman; Nicolas Wentzensen; Jurriaan Brouwer-Visser; Maria Jose Cossio; Kathleen D Whitney; Herbert Yu; Marc J Gunter; Gloria S Huang Journal: Cancer Causes Control Date: 2016-04-28 Impact factor: 2.506